Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Abstract Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized contr...

Full description

Bibliographic Details
Main Authors: Richard G. Wunderink, Evangelos J. Giamarellos-Bourboulis, Galia Rahav, Amy J. Mathers, Matteo Bassetti, Jose Vazquez, Oliver A. Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L. Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L. Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N. Dudley, Keith S. Kaye
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-10-01
Series:Infectious Diseases and Therapy
Subjects:
Best available therapy
Carbapenem-resistant Enterobacteriaceae
Meropenem–vaborbactam
Randomized clinical trial
TANGO II
Online Access:http://link.springer.com/article/10.1007/s40121-018-0214-1

Internet

http://link.springer.com/article/10.1007/s40121-018-0214-1

Similar Items